Levee Medical

Executive Summary

Levee Medical is a private medical device company based in San Francisco, focused on addressing post-prostatectomy urinary incontinence, a common complication affecting quality of life in prostate cancer survivors. The company's lead product, the Voro® Urologic Scaffold, is an absorbable implant designed to provide structural support to the urethral sphincter, thereby reducing incontinence. The device is currently in pivotal clinical trials, representing the final stage before regulatory submission. If successful, Voro could become a first-in-class solution for a large and underserved patient population, with over 100,000 radical prostatectomies performed annually in the U.S. The company operates in a competitive landscape but targets a clear unmet need, with potential for significant market adoption. However, the technology is not yet approved, and regulatory and clinical risks remain. Levee's progress through the pivotal trial will be a key determinant of its future.

Upcoming Catalysts (preview)

• Q4 2026Pivotal Trial Completion70% success
• Q2 2027FDA 510(k) Submission60% success